NASDAQ · MDCX
Healthcare · Biotechnology
$0.17
Down-$0.00 (-2.00%)
Updated Sep 10, 2026, 2:20 PM
SID Score
2.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
MDCX closed at $0.17 after 20 trading sessions, down 48.54% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $0.1636 | $0.1718 | $0.1636 | $0.1704 | 4.94M |
| Sep 8, 2026 | $0.172 | $0.2025 | $0.1611 | $0.17 | 23.39M |
| Sep 4, 2026 | $0.1622 | $0.183 | $0.16 | $0.172 | 15.87M |
| Sep 3, 2026 | $0.205 | $0.2067 | $0.1512 | $0.1705 | 96.66M |
| Sep 2, 2026 | $0.2515 | $0.26 | $0.2515 | $0.2599 | 354.28K |
| Sep 1, 2026 | $0.26 | $0.2615 | $0.2501 | $0.2512 | 480.33K |
| Aug 31, 2026 | $0.255 | $0.2655 | $0.2525 | $0.2618 | 417K |
| Aug 28, 2026 | $0.2662 | $0.2712 | $0.2553 | $0.2577 | 588.87K |
| Aug 27, 2026 | $0.2696 | $0.275 | $0.262 | $0.2678 | 702.71K |
| Aug 26, 2026 | $0.2709 | $0.2709 | $0.2554 | $0.2685 | 733.89K |
| Aug 25, 2026 | $0.2536 | $0.275 | $0.2536 | $0.261 | 860.4K |
| Aug 24, 2026 | $0.27 | $0.275 | $0.255 | $0.2574 | 826.14K |
| Aug 21, 2026 | $0.2664 | $0.275 | $0.2652 | $0.2718 | 852.64K |
| Aug 20, 2026 | $0.27 | $0.28 | $0.2608 | $0.2722 | 2.4M |
| Aug 19, 2026 | $0.2617 | $0.2672 | $0.2517 | $0.2645 | 1.88M |
| Aug 18, 2026 | $0.265 | $0.2662 | $0.2425 | $0.2633 | 2.49M |
| Aug 17, 2026 | $0.2811 | $0.284 | $0.26 | $0.26 | 2.59M |
| Aug 14, 2026 | $0.354 | $0.362 | $0.28 | $0.2801 | 2.77M |
| Aug 13, 2026 | $0.3318 | $0.368 | $0.325 | $0.354 | 1.24M |
| Aug 12, 2026 | $0.3599 | $0.3599 | $0.331 | $0.3311 | 1.2M |
The latest Smart Investors Daily articles mentioning MDCX.
MDCX research
Company profile and research snapshot.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 20, 2026 | D. Boral Capital | Buy | — |
| Mar 19, 2026 | D. Boral Capital | Buy | — |
| Mar 9, 2026 | D. Boral Capital | Buy | — |
| Dec 15, 2025 | D. Boral Capital | Buy | — |
| Nov 17, 2025 | D. Boral Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 16, 2026
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic
Benzinga · Mar 9, 2026
Benzinga · Mar 9, 2026
Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today
Benzinga · Feb 10, 2026
Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MDCX.
